Informational only — Not medical advice. Always consult a licensed healthcare provider.

Community data Updated 2 months ago

Indications & Uses

Adrebloc IV Injection is indicated for:

Pharmacology

Esmolol Hydrochloride is a beta-1 selective (cardioselective) adrenergic receptor blocking agent. It starts working quickly and acts for a very short time. At therapeutic doses it has no significant intrinsic sympathomimetic activity and no significant membrane stabilizing activity. After an intravenous infusion, its elimination half-life is approximately 9 minutes.

Esmolol Hydrochloride blocks the beta 1 receptors, which are found mainly in cardiac muscle. This preference isn't absolute, though. At higher doses it starts to block beta 2 receptors as well, and these are found mainly in the bronchial and vascular muscle.

Dosage Reference

Reference Information Only

Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.

Adults:

Esmolol Hydrochloride is given intravenously. The dose is adjusted according to the ventricular rate or blood pressure, at intervals of 4 minutes or more.

For supraventricular tachycardia (SVT) or noncompensatory sinus tachycardia, a loading dose of 500 mcg per kg, infused over one minute, is optional. Then 50 mcg per kg per minute is given for the next 4 minutes. The dose can be adjusted as needed, up to a maximum of 200 mcg per kg per minute. Additional loading doses may be given.

For perioperative tachycardia and hypertension, the loading dose is 500 mcg per kg over 1 minute for gradual control. For immediate control it is 1 mg per kg over 30 seconds. After that, 50 mcg per kg per minute is given for gradual control, or 150 mcg per kg per minute for immediate control. The dose is adjusted up to a maximum of 200 mcg per kg per minute for tachycardia, or 300 mcg per kg per minute for hypertension.

Side Effects

The most common side effects of Esmolol Hydrochloride, seen in more than 10% of people, are low blood pressure with symptoms (such as sweating and dizziness) and low blood pressure without any symptoms.

Cautions & Contraindications

Warnings & Precautions

Esmolol Hydrochloride can cause low blood pressure, a slow heart rate and cardiac failure. If any of these happen, reduce the dose or stop the medicine. It may make reactive airway disease worse. In people with diabetes mellitus, esmolol increases the effect of hypoglycemic agents and masks hypoglycemic tachycardia. In untreated pheochromocytoma there is a risk of unopposed alpha-agonism and severe hypertension. If the medicine is stopped suddenly in patients with coronary artery disease, there is a risk of myocardial ischemia.

Contraindications

Esmolol hydrochloride should not be used in people with any of these conditions: Severe sinus bradycardia, heart block greater than first degree, sick sinus syndrome, decompensated heart failure, cardiogenic shock, and pulmonary hypertension. It is also not to be used in anyone with known hypersensitivity to esmolol. Coadministration of IV cardiodepressant calcium-channel antagonists (e.g. verapamil) in close proximity to esmolol hydrochloride is also a contraindication.

Pregnancy & Breastfeeding

Esmolol Hydrochloride is Pregnancy Category C. In rabbits, doses of about 8 times the maximum human maintenance dose (300 mcg/kg/min) caused more fetal resorptions, with little toxicity to the mother. There are no adequate and well-controlled studies in pregnant women, so Esmolol Hydrochloride should be used in pregnancy only if the likely benefit justifies the possible risk to the fetus.

It is not known whether the medicine passes into human milk. Many drugs do, and Esmolol Hydrochloride could cause serious adverse reactions in nursing infants. So a decision should be made either to stop nursing or to stop the medicine, taking into account how important the medicine is to the mother.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Use in Special Populations

Pediatric Use: The safety and effectiveness of Esmolol Hydrochloride in children have not been established.

Geriatric Use: Clinical studies of Esmolol Hydrochloride did not include enough people aged 65 and over to show whether they respond differently from younger people.

Hepatic Impairment: No special precautions are needed in patients with liver impairment, because Esmolol Hydrochloride is broken down by red-blood cell esterases.

Renal Impairment: No dose adjustment is required for esmolol in patients with kidney impairment who are receiving a maintenance infusion of esmolol 150 mcg/kg for 4 hours.

Storage

Store Esmolol Hydrochloride below 25°C, away from light and moisture. Keep it out of the reach of children.

Common questions about Adrebloc IV Injection 100 mg

What is Adrebloc IV Injection 100 mg Injection?

Adrebloc IV Injection 100 mg Injection is a medicine that contains Esmolol Hydrochloride. It is made by General Pharmaceuticals Ltd, Unit-2. It belongs to the Anti adrenergic agent (Beta blockers) group of medicines.

What is Adrebloc IV Injection used for?

Adrebloc IV Injection is used for: Hypertension, Cardiac Arrhythmia.

What are the side effects of Adrebloc IV Injection?

The most common side effects of Esmolol Hydrochloride, seen in more than 10% of people, are low blood pressure with symptoms (such as sweating and dizziness) and low blood pressure without any symptoms.

Can I take Adrebloc IV Injection during pregnancy or while breastfeeding?

Esmolol Hydrochloride is Pregnancy Category C. In rabbits, doses of about 8 times the maximum human maintenance dose (300 mcg/kg/min) caused more fetal resorptions, with little toxicity to the mother. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

How should I store Adrebloc IV Injection?

Store Esmolol Hydrochloride below 25°C, away from light and moisture. Keep it out of the reach of children.

Do I need a prescription for Adrebloc IV Injection?

Adrebloc IV Injection is a prescription (Rx) medicine. Take it as your doctor advises.

Last updated: 15 Aug 2026